Xu Yuehe, Wei Chao, Ma Li, Zhao Long, Li Dongfang, Lin Yiliang, Zhou Qingjun, Xie Lixin, Wang Fuyan
Eye Institute of Shandong First Medical University, Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Key Laboratory of Eye Diseases, School of Ophthalmology, Shandong First Medical University, Qingdao 266071, China.
Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore.
J Control Release. 2025 Apr 10;380:630-646. doi: 10.1016/j.jconrel.2025.02.030. Epub 2025 Feb 16.
Mesenchymal stem cell (MSC)-derived exosomes have the potential to sustain immune homeostasis and facilitate tissue regeneration, and those effects can be potentiated under three-dimensional (3D) cell culture conditions. Nevertheless, whether exosomes derived from 3D-cultured MSCs (3D-Exos) exert therapeutic effects on the injured corneas and the underlying mechanism remain unclear. In this study, MSCs are cultured in a gelatin methacryloyl (GelMA) hydrogel to produce 3D-Exos. In vitro experiments revealed that the 3D-cultured MSCs maintained their stemness, the exosomes were produced in better yield, and the generated 3D-Exos possess exceptional anti-inflammatory, pro-proliferative and tissue remodeling properties. Moreover, the 3D-Exos that were delivered by the GelMA hydrogel displayed a sustained release profile for multi-dimensional injured cornea repair. Extensive in vitro studies further demonstrated that, compared with the two-dimensional (2D)-Exo-hydrogel treatment, 3D-Exo-hydrogel treatment yielded better recovery of corneal morphology and function, as revealed by mitigated inflammation, promoted corneal epithelium and limbus repair, and reduced scar formation in the stroma. Mechanistically, the 3D-Exos promoted the proliferation of cornea-derived cells and reduced the release of inflammatory factors via miR-150-5p targeting of the PDCD4 gene. Overall, the developed 3D-Exo-hydrogel sustained release system may represent a promising cell-free strategy for the treatment of various corneal diseases.
间充质干细胞(MSC)衍生的外泌体具有维持免疫稳态和促进组织再生的潜力,并且在三维(3D)细胞培养条件下这些作用可以增强。然而,源自3D培养的MSC的外泌体(3D-Exos)是否对受损角膜发挥治疗作用及其潜在机制仍不清楚。在本研究中,将MSC培养在甲基丙烯酰化明胶(GelMA)水凝胶中以产生3D-Exos。体外实验表明,3D培养的MSC保持其干性,外泌体产量更高,并且所产生的3D-Exos具有卓越的抗炎、促增殖和组织重塑特性。此外,由GelMA水凝胶递送的3D-Exos在多维受损角膜修复中显示出持续释放特性。广泛的体外研究进一步证明,与二维(2D)-Exo-水凝胶治疗相比,3D-Exo-水凝胶治疗在角膜形态和功能恢复方面效果更好,表现为炎症减轻、角膜上皮和角膜缘修复促进以及基质中瘢痕形成减少。机制上,3D-Exos通过miR-150-5p靶向PDCD4基因促进角膜来源细胞的增殖并减少炎症因子的释放。总体而言,所开发的3D-Exo-水凝胶持续释放系统可能代表一种用于治疗各种角膜疾病的有前景的无细胞策略。